- $2.96m
- -$0.42m
- $1.19m
- 17
- 46
- 18
- 16
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.66 | ||
| Price to Tang. Book | 0.66 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.21 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -158.29% | ||
| Return on Equity | -185.15% | ||
| Operating Margin | -547.64% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.14 | 0.26 | 0.6 | 1.02 | 1.19 | 2.24 | 4.51 | 32.06% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
SenesTech, Inc. develops and commercializes products for managing animal pest populations, initially rat populations, through fertility control. The Company has two product lines of fertility control products: ContraPest and Evolve. Its product ContraPest, is a liquid bait containing the active ingredients 4-vinylcyclohexene diepoxide (VCD) and triptolide. ContraPest targets the reproductive systems of both male and female Norway and roof rats beginning with the first breeding cycle following consumption, which can lead to sustained reductions of the rat population. ContraPest is a highly palatable liquid formulation that reduces fertility in both male and female rats. Additionally, ContraPest does not cause illness in rats, and, therefore, it does not change behavior or result in bait aversion. ContraPest offers a new tool used in coordination with rodenticides as part of an integrated pest management program. The Company's technology can also be applied to other mammalian species.
Directors
- Jamie Morrison NEC (48)
- Kenneth Siegel CEO (65)
- Thomas Chesterman CFO (61)
- Steven Krause EVP (61)
- Kim Wolin EVP (65)
- Nicole Williams OTH (42)
- Delphine Chiavarini IND (45)
- Marc Dumont IND (77)
- Phil Grandinetti IND (49)
- K. Kavanagh IND (51)
- Jake Leach IND (43)
- Matthew Szot IND (46)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- November 12th, 2015
- Public Since
- December 8th, 2016
- No. of Shareholders
- 691
- No. of Employees
- 25
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 5,144,632
- Address
- 23460 N. 19th Ave, Suite 110, PHOENIX, 85027
- Web
- https://senestech.com/
- Phone
- +1 9287794143
- Auditors
- M&K CPAS PLLC
Upcoming Events for SNES
Senestech Inc Annual Shareholders Meeting
Q2 2024 Senestech Inc Earnings Release
Q3 2024 Senestech Inc Earnings Release
Similar to SNES
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the SenesTech share price?
As of Today at 23:11 UTC, shares in SenesTech are trading at $0.59. This share price information is delayed by 15 minutes.
How has the SenesTech share price performed this year?
Shares in SenesTech last closed at $0.59 and the price had moved by -96.01% over the past 365 days. In terms of relative price strength the SenesTech share price has underperformed the S&P500 Index by -96.82% over the past year.
What are the analyst and broker recommendations for SenesTech?
The overall consensus recommendation for SenesTech is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the SenesTech dividend yield?
SenesTech does not currently pay a dividend.
Does SenesTech pay a dividend?
SenesTech does not currently pay a dividend.
When does SenesTech next pay dividends?
SenesTech does not currently pay a dividend.
How do I buy SenesTech shares?
To buy shares in SenesTech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of SenesTech?
As of the previous close price of $0.59, shares in SenesTech had a market capitalisation of $3.03m.
Where are SenesTech shares listed?
Here are the trading details for SenesTech:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: SNES
What kind of share is SenesTech?
Based on an overall assessment of its quality, value and momentum SenesTech is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a SenesTech share price forecast for 2024?
The analyst consensus target price for shares in SenesTech is $3.50. That is 493.62% above the last closing price of $0.59.
Analysts covering SenesTech currently have a consensus Earnings Per Share (EPS) forecast of -$1.10 for the next financial year.
What is the trend in the SenesTech share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like SenesTech. Over the past six months, its share price has underperformed the S&P500 Index by -34.79%.
As of the last closing price of $0.59, shares in SenesTech were trading -68.06% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the SenesTech PE Ratio?
The SenesTech PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.59.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of SenesTech?
SenesTech's management team is headed by:
- Jamie Morrison - NEC
- Kenneth Siegel - CEO
- Thomas Chesterman - CFO
- Steven Krause - EVP
- Kim Wolin - EVP
- Nicole Williams - OTH
- Delphine Chiavarini - IND
- Marc Dumont - IND
- Phil Grandinetti - IND
- K. Kavanagh - IND
- Jake Leach - IND
- Matthew Szot - IND